To this day, the world’s supply of radioisotopes is produced in a handful of unreliable nuclear reactors. At these facilities, Mo-99 is collected as a by-product of the fission of potentially dangerous weapons grade uranium. Security concerns aside, the world has experienced continual supply shortages due to the degeneration of these old facilities. Our innovation is creating a new radioisotope production process that is cleaner, more reliable, more diversified, and more easily scalable than reactor based production.
A linear accelerator, often referred to as a LINAC, is a particle accelerator that fires electrons, neutrons, or protons in a straight line. Though researchers have had the ability to produce radioisotopes with the technology for decades, there were concerns about whether LINAC’s would ever be able to produce an economically competitive product at scale. CII has solved those challenges.
CII was able to achieve this by commercializing state-of-the-art research and technology created by The Canadian Lightsource (CLS). Our proprietary LINAC technology and production methods were developed with the support of the Government of Canada, who provided funding to create alternative medical isotope production methods. Several competing potential solutions were funded to address radioisotope supply shortages in Canada and the world. CII’s LINAC based method showed the most potential and is the first viable large-scale production alternative.
Our proprietary solution can produce pure Mo-99 at a lower cost per dose than competing technologies, due to lower distribution and processing costs. Furthermore, our production facilities are more easily scalable than reactors and more supply can be brought online to meet growing world demand,
CII Tc-99m is undergoing clinical trials and will soon be available for purchase.
Contact us for more information!